Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05681039
Status:
RECRUITING
Last Update Posted:
2024-06-04
First Post:
2022-12-15
Brief Title:
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma OCSCC
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-02
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-15
First Submit QC Date:
December 27 2022
Study First Post Date:
2023-01-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-06
Last Update Post Date:
2024-06-04
Last Update Post Date Type:
ACTUAL